Premium
Human immunodeficiency virus‐related non‐Hodgkin lymphoma
Author(s) -
Spina Michele,
Vaccher Emanuela,
Juzbasic Senka,
Milan Isabella,
Nasti Guglielmo,
Talamini Renato,
Fasan Marco,
Antinori Andrea,
Nigra Ezio,
Tirelli Umberto
Publication year - 2001
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20010701)92:1<200::aid-cncr1310>3.0.co;2-a
Subject(s) - medicine , etoposide , lymphoma , cyclophosphamide , chemotherapy , non hodgkin's lymphoma , gastroenterology , surgery , refractory (planetary science) , doxorubicin , human immunodeficiency virus (hiv) , immunology , physics , astrobiology
BACKGROUND The prognosis of patients with human immunodeficiency virus (HIV)‐related non‐Hodgkin lymphoma (NHL) is poor. In fact, despite a high complete response (CR) rate, approximately 50% of these patients die from progressive lymphoma. METHODS From November 1994 to April 2000, the authors treated 40 patients with resistant or recurrent HIV‐related NHL with a 96‐hour continuous intravenous infusion of cyclophosphamide (187.5 mg/m 2 per day), doxorubicin (12.5 mg/m 2 per day), and etoposide (60 mg/m 2 per day). RESULTS The median number of cycles administered was two (range, one to six cycles). A CR was documented in 4 of 40 patients (10%), and a partial remission (PR) was documented in 7 of 40 patients (18%). The CR median duration was 6 months (range, 4–30+ months), whereas PRs lasted for 5 months (range, 2–8 months). The overall median survival was 4 months (range, < 1–33 months), and the median survival for responding patients was 10 months. CONCLUSIONS The current data confirm that infusional cyclophosphamide, doxorubicin, and etoposide is active in patients with refractory or recurrent HIV‐related NHL. However, the median survival of these patients remains poor, and the other innovative approaches should be used. Cancer 2001;92:200–6. © 2001 American Cancer Society.